Cefalonium Intramammary Infusion Veterinary Grade API is a first-generation cephalosporin supplied as cefalonium dihydrate crystalline powder. The molecule carries a 4-carbamoylpyridinium methyl group at the C-3 position of the cephem nucleus and a 2-thienylacetyl side chain at C-7. These structural elements distinguish it from cefazolin, which has a 5-methyl-1,3,4-thiadiazol-2-ylthiomethyl group at C-3, and from ceftiofur, a third-generation cephalosporin with broader Gram-negative activity. The product is not a finished intramammary syringe; it is an active pharmaceutical ingredient that downstream manufacturers may formulate into sterile intramammary infusions, tablets, injections, capsules, powders, granules, premixes, or solutions. However, the regulatory and pharmacokinetic data for cefalonium are concentrated in dry-cow intramammary therapy. For oral capsules or tablets in monogastric species, published data for this specific configuration are limited, and systemic bioavailability cannot be assumed from the chemical class alone.

Manufacturer-specific model codes may distinguish the micronised sterile-suspension grade from the sieved non-sterile grade intended for premix or granulation; the exact designation is assigned in the API master file. Release documentation normally includes identification by infrared absorption spectrophotometry (Ph. Eur. 2.2.24) and by HPLC retention time against a reference standard. Assay is performed by liquid chromatography using the general methods in Ph. Eur. 2.2.29 or USP ⟨621⟩. Related substances are determined by gradient HPLC with UV detection; thresholds for unspecified impurities follow VICH GL10 and VICH GL11. Residual solvents are controlled by headspace gas chromatography under VICH GL18 / ICH Q3C, and elemental impurities by ICP-MS under VICH GL19 / ICH Q3D. The certificate of analysis should state water content by Karl Fischer titration (Ph. Eur. 2.5.12), because the dihydrate crystal contains water of crystallisation that affects assay on the as-is basis. A typical assay acceptance interval for a cephalosporin API is 98.0–102.0% on the dried basis, but the registered specification may be tighter. The API should be stored below 25 °C in sealed aluminium foil with desiccant; exposure above 60% RH at 25 °C can increase surface water and reduce flowability.

What Distinguishes a C-3 4-Carbamoylpyridinium Cephalosporin from Cefazolin or Ceftiofur in Mastitis Therapy?

The C-3 quaternary pyridinium group in cefalonium creates a permanently charged centre under physiological pH conditions. This is the key difference from cefazolin, whose C-3 substituent is an uncharged thiadiazolylthiomethyl group. The permanent charge increases water solubility and reduces passive diffusion across lipid membranes. After intramammary infusion into the bovine udder, the drug is retained longer in the aqueous and tissue compartments of the gland, which is the desired profile for dry-cow therapy. The same charge limits oral absorption and restricts distribution after systemic administration, which explains why injectable or oral use would not be clinically interchangeable with intramammary use without separate pharmacokinetic studies.

Spectrum differences are also clinically relevant. Cefalonium is most active against Gram-positive mastitis pathogens such as Staphylococcus aureus, Streptococcus uberis, and Streptococcus dysgalactiae; its activity against Escherichia coli and other Enterobacteriaceae is lower. Ceftiofur is a third-generation cephalosporin with expanded Gram-negative coverage and is used in lactating-cow mastitis in some jurisdictions. Cefazolin has a similar Gram-positive spectrum but is not approved for intramammary dry-cow therapy in most dairy markets. Published MIC distributions for cefalonium vary by isolate collection and by method; no harmonised EUCAST veterinary breakpoint is available for cefalonium in bovine mastitis, so susceptibility reports should be interpreted using clinical outcome data and local breakpoints.

For sterile intramammary suspension manufacture, dry milling on a spiral jet mill is typically used to reduce the dihydrate crystals to a low-micrometre particle size. The exact D90 is product-specific; published data for this specific API configuration are limited. Laser diffraction analysis according to Ph. Eur. 2.9.31 or USP ⟨429⟩ provides D10, D50, and D90 values. Overgrinding increases electrostatic charging, reduces bulk density, and can create agglomerates that do not wet readily in an oily vehicle. Batch-to-batch variation in crystal habit from recrystallisation may alter the angle of repose and require cone milling before blending. For dry granulation or tablet manufacture, a coarser sieve-cut fraction may be acceptable, and sieve analysis according to Ph. Eur. 2.9.38 is used instead of laser diffraction.

Moisture control during milling is a process bottleneck. If the milling gas is not dehumidified below 40% RH, surface water adsorption can occur on newly created crystal surfaces. This surface water is measured by a fast Karl Fischer oven method and is distinguished from the water of crystallisation in cefalonium dihydrate. A nitrogen-purged mill is preferred because oxygen and heat accelerate β-lactam degradation. The milled API is discharged into double-lined polyethylene bags inside fibre drums and sealed under nitrogen; the material should be equilibrated to 15–25 °C before packaging to prevent condensation.

Moisture, Polymorph, and Endotoxin Barriers for Sterile Intramammary Infusions

Because the raw API is not necessarily sterile, the finished-product manufacturer must either sterile-filter or terminally sterilise the formulation. For an oily intramammary suspension, sterile filtration of the API solution is usually not feasible because the API is suspended, not dissolved. The API may be sterilised by dry heat or gamma irradiation if validated; the β-lactam ring can undergo free-radical degradation under gamma radiation, so the irradiation dose must be justified by degradation product data. A finite bacterial endotoxin limit is mandatory for intramammary products. The limit is set from the maximum dose per bovine quarter; for a 250 mg cefalonium syringe, a typical limit is ≤0.20 EU/mg for the finished product, but the registered dossier controls the final value. The raw API should be tested by the Limulus amoebocyte lysate method according to Ph. Eur. 2.6.14 before release for sterile compounding.

Polymorphic consistency is controlled by X-ray powder diffraction. A change in crystal form can alter dissolution rate in the udder and suspension stability. The manufacturer should compare each batch against the reference pattern; a shift in the characteristic diffraction peaks indicates a form change. The dihydrate form is the usual commercial form; anhydrous material can be generated by aggressive drying above 60 °C, which is not recommended because it may increase the rate of hydrolysis after reconstitution.

Stability-indicating HPLC for cefalonium dihydrate typically employs a reversed-phase C18 column with a phosphate buffer and acetonitrile gradient. The detector wavelength is selected near the UV maximum of the cephem chromophore, commonly 254 nm or 270 nm; the exact wavelength is defined in the registered method. System suitability requires resolution between cefalonium and the primary degradation product. The main degradation route under alkaline conditions is β-lactam ring opening, followed by formation of the inactive lactone. Under acidic conditions, the carbamoyl group of the pyridinium substituent can hydrolyse. These degradation products must be quantified against the API reference standard; unspecified degradation products are controlled at a threshold typically ≤0.10%, but the final specification is dossier-specific.

When the Same API Powder Is Specified for Tablets, Injections, and Premixes, Process Validation Boundaries Change

The API supply chain may list tablets, injections, capsules, powders, granules, premixes, and solutions as potential dosage forms, but the manufacturing process must be revalidated for each route. For tablets and capsules, the β-lactam ring is sensitive to moisture, heat, and basic pH. Direct compression or dry granulation is preferred; wet granulation with aqueous binders is not recommended unless the process is demonstrated to keep the granulation temperature below 40 °C and the moisture content below 2.0% at the point of compression. For injectable solutions, the API must be dissolved in a vehicle in which it is chemically stable; the quaternary pyridinium group can cause precipitation when the pH shifts above 7.0, so the formulation requires a buffer system with an acidic pH. For premix powders and granules, the API is blended with feed carriers; blend uniformity is verified using a validated near-infrared or HPLC method. If a pharmacopoeial general chapter is applied, Ph. Eur. 2.9.40 or USP ⟨905⟩ may be used for finished dosage units.

The compound should not be dry-blended with amine-functionalised carriers or alkaline minerals, because nucleophilic amines accelerate β-lactam ring opening and reduce potency. For a dry-cow intramammary product, the relevant performance attribute is not oral bioavailability but the duration of milk concentrations above the MIC for the dry period. Cefalonium is formulated as an oily suspension that releases slowly from the udder. The API particle size distribution and polymorphic form influence this release. In contrast, a tablet or capsule would require the API to survive gastric pH and be absorbed through the intestinal epithelium; cefalonium's permanent charge limits passive absorption, and published data for this specific configuration are limited. An injectable solution would produce a different pharmacokinetic curve and may require renal excretion data and residue withdrawal periods.

Compared with cloxacillin dry-cow intramammary products, cefalonium is a cephalosporin with a broader Gram-negative spectrum than the penicillinase-resistant penicillin but is not β-lactamase-stable in the same way. Cloxacillin products are typically formulated as benzathine salts for prolonged release, whereas cefalonium dry-cow products are formulated as intramammary suspensions of the dihydrate. The choice between them depends on local mastitis pathogen epidemiology and susceptibility data. For intramammary infusion, the manufacturer must also control the oily vehicle viscosity, syringeability, and sedimentation rate; these parameters are measured on a rotational rheometer with cone-plate geometry according to ISO 3219 or on a forced-displacement syringe test according to ISO 7886-1 for the finished device.

Bulk density and tapped density are measured according to Ph. Eur. 2.2.42 or USP ⟨616⟩. Batch-to-batch variation in bulk density can interfere with the fill weight of powders and granule mixtures. The API is packaged in food-grade polyethylene liners inside fibre drums with desiccant sachets. Each drum is labelled with the API name, batch number, manufacturing date, retest date, storage temperature, and the manufacturer’s model grade. A retest period of 24 months or 36 months is common for dry cephalosporin APIs, but the approved retest date must be supported by stability data under ICH/VICH conditions, specifically 25 °C / 60% RH for long-term and 40 °C / 75% RH for accelerated storage.